InvestSMART

Australian Clinical Labs Limited (ASX: ACL) - Announcements

- Current share price for ACL : $2.880

ASX company news and announcements for Australian Clinical Labs Limited (ACL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Australian Clinical Labs Limited (ACL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Australian Clinical Labs Limited (ACL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Australian Clinical Labs Limited (ACL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$537 Alchemia Rights Issue Oversubscribed 24 Dec 2009 8:33AM $0.650 $2.880 risen by 343.08%
$537 Rights Issue Information Booklet 25 Nov 2009 9:27AM $0.675 $2.880 risen by 326.67%
$537 Letter to Shareholders re Rights Issue 25 Nov 2009 9:27AM $0.675 $2.880 risen by 326.67%
$537 ACL Appendix 4C 23 Oct 2009 12:16PM $0.540 $2.880 risen by 433.33%
$537 Preliminary Final Report 26 Aug 2009 7:35PM $0.475 $2.880 risen by 506.32%
$537 Quarterly Commitments Report Appendix 4C 31 Jul 2009 10:57AM $0.390 $2.880 risen by 638.46%
$537 Fondaparinux ANDA accepted by FDA for Review 11 May 2009 10:13AM $0.395 $2.880 risen by 629.11%
$537 Appendix 4C 22 Apr 2009 2:38PM $0.410 $2.880 risen by 602.44%
$537 Cancer Drug Collaboration 19 Mar 2009 10:06AM $0.305 $2.880 risen by 844.26%
$537 ANDA Filing 13 Mar 2009 9:46AM $0.230 $2.880 risen by 1,152.17%
$537 Trading Halt 11 Mar 2009 9:58AM $0.175 $2.880 risen by 1,545.71%
$537 Half Yearly Report and Accounts 25 Feb 2009 3:09PM $0.145 $2.880 risen by 1,886.21%
$537 Appendix 4C - quarterly 29 Jan 2009 1:45PM $0.140 $2.880 risen by 1,957.14%
$537 Milestone payments Dr Reddy 16 Dec 2008 11:37AM $0.125 $2.880 risen by 2,204%
$537 Alchemia Announces Prudent Cash Management Strategy 28 Oct 2008 9:58AM $0.175 $2.880 risen by 1,545.71%
$537 FDA approves open IND for HA-Irinotecan phase 3 23 Oct 2008 1:23PM $0.190 $2.880 risen by 1,415.79%
$537 Key Fondaparinux patent allowed by US Patent Office 21 Oct 2008 11:44AM $0.220 $2.880 risen by 1,209.09%
$537 Appendix 4C 20 Oct 2008 10:07AM $0.215 $2.880 risen by 1,239.53%
$537 IND Filing for Anti-Cancer Agent 29 Sep 2008 10:53AM $0.220 $2.880 risen by 1,209.09%
$537 Preliminary Final Report 22 Aug 2008 4:14PM $0.290 $2.880 risen by 893.10%
$537 Appendix 4C - Quarterly Commitments Report 31 Jul 2008 8:29AM $0.295 $2.880 risen by 876.27%
$537 Alchemia patents granted for generic fondaparinux 23 Jun 2008 11:07AM $0.355 $2.880 risen by 711.27%
$537 Appendix 4C - Quarterly Commitments Report 15 Apr 2008 8:27AM $0.415 $2.880 risen by 593.98%
$537 Alchemia Appendix 4D 25 Feb 2008 10:29AM $0.335 $2.880 risen by 759.70%
$537 Alchemia announces successful Pre-IND meeting with the US FD 1 Feb 2008 10:08AM n/a $2.880 n/a

926 - 950 of 1019 results

Page 38 of 41

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.